CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics.
Guanglin ZhuXinzhi ZhouMingzhang WenJianjun QiaoGuo LiYuan YaoPublished in: Biodesign research (2024)
The CRISPR-Cas13 system has emerged as a revolutionary tool for RNA editing, offering new opportunities for the development of nucleic acid therapeutics. Unlike DNA-targeting CRISPR-Cas9, Cas13 targets and cleaves RNA, enabling gene silencing and preventing genomic instability. Its applications include suppressing disease-causing genes, correcting splicing errors, and modulating immune responses. Despite these advances, challenges persist, such as the need to refine specificity, mitigate off-target impacts, and ensure effective delivery. This review provides an overview of the CRISPR-Cas13 mechanism, elucidating its role in RNA-targeted therapies and its transformative potential for disease treatment. Furthermore, it addresses the ongoing challenges that the scientific community is striving to overcome.
Keyphrases
- crispr cas
- nucleic acid
- genome editing
- immune response
- small molecule
- signaling pathway
- mental health
- healthcare
- emergency department
- gene expression
- patient safety
- cancer therapy
- genome wide
- drug delivery
- toll like receptor
- climate change
- circulating tumor
- risk assessment
- inflammatory response
- human health
- adverse drug
- smoking cessation
- circulating tumor cells
- electronic health record
- genome wide analysis